Compare Tyson Foods, Inc. (TSN) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tyson Foods, Inc. vs Viatris Inc — how do they compare? Tyson Foods, Inc. trades at $55.83 (market cap $19.85B), while Viatris Inc trades at $16.32 (market cap $18.69B). The key difference: Tyson Foods, Inc. and Viatris Inc are close in size by market cap, and Tyson Foods, Inc. pays the higher dividend (3.62%). Which is the better fit depends on your goals.
| TSN | VTRS | |
|---|---|---|
Market Cap | $19.85B | $18.69B |
Sector | Consumer Staples | Health |
52-Week High | $68.75 | $17.86 |
52-Week Low | $50.72 | $9.49 |
Enterprise Value | $27.12B | $30.80B |
Dividend Yield | 3.62% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Tyson Foods (TSN) trades at $57.16, down 1.52% on the day, amid a bearish technical signal. The company reported mixed Q3 2026 earnings, beating EPS estimates but missing revenue expectations, with beef segment losses weighing on results. Analyst consensus is a Buy with a $68.50 price target, but technical indicators show selling pressure. Recent news highlights debt tender offers and a maintained dividend, while cash flow trends show volatility.
The outlook is cautious; strong chicken and prepared foods segments provide stability, but persistent beef losses and volume declines pose near-term risks. Valuation metrics like P/E of 34.83 appear elevated relative to modest profitability, yet the stock trades below analyst targets, suggesting potential upside if operational challenges ease.
Viatris (VTRS) trades at $16.28, down 0.91% on the day, with a bearish technical signal and mixed fundamentals. The company reported a net loss of $3.51 billion in 2025 despite recent quarterly earnings beats, including Q2 2026 EPS of $0.69 versus $0.62 expected. Revenue declined to $14.30 billion in 2025, but operational cash flow remains strong at $2.32 billion. Recent news highlights divestitures and FDA approval for Gwyn Lo, a contraceptive patch.
Outlook is cautious due to persistent losses and high P/E of 236.2, but dividend payments and cost-cutting efforts offer stability. Risks include competitive pressures and debt levels, while analyst consensus leans hold. The stock's value hinges on margin improvement and debt reduction progress.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Tyson Foods, Inc.
Tyson Foods is the largest U.S. producer of processed chicken and beef. It's also a large producer of processed pork and protein-based products under the brands Jimmy Dean, Hillshire Farm, Ball Park, Sara Lee, Aidells, State Fair, and Raised & Rooted, to name a few. Tyson sells 81% of its products through various U.S. channels, including retailers (47% in fiscal 2021), food service (32%), and other packaged food and industrial companies (10%). In addition, 11% of the company's revenue comes from exports to Canada, Mexico, Brazil, Europe, China, and Japan.
Read more on TSN →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
